Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif

Leukemia

Volumn 24, Issue 11, 2010, Pages 1901-1909

  Abrahamsen, I W ^a,b,c   Stronen, E ^a,b,c   Walchli S ^b   Johansen, J N ^b   Kjellevoll, S ^b   Kumari, S ^b   Komada, M ^b   Gaudernack, G ^b   Tjonnfjord, G ^a,c   Toebes, M ^d   Schumacher, T N ^d   Lund Johansen, F ^a   Olweus, J ^b,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

allo reactivity; chronic lymphocytic leukemia; graft versus leukemia; immunotherapy; public T cell receptor; T cell receptor bias

Indexed keywords

CD20 ANTIGEN; HLA A ANTIGEN; T LYMPHOCYTE RECEPTOR;

ARTICLE; B CELL LEUKEMIA; CD8[+] T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; COMPLEMENTARITY DETERMINING REGION; DENDRITIC CELL; GRAFT DYSFUNCTION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 78149470173     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.186     Document Type: Article

References (43)

1. Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008; 112: 4371-4383.
2. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Gao L, Downs AM, Stauss HJ. Immunotherapy with CTL restricted by nonself MHC. Methods Mol Med 2005; 109: 215-228.
4. Matzinger P, Bevan MJ. Hypothesis: why do so many lymphocytes respond to major histocompatibility antigens? Cell Immunol 1977; 29: 1-5.
5. Housset D, Malissen B. What do TCR-pMHC crystal structures teach us about MHC restriction and alloreactivity? Trends Immunol 2003; 24: 429-437.
6. Huseby ES, Crawford F, White J, Kappler J, Marrack P. Negative selection imparts peptide specificity to the mature T cell repertoire. Proc Natl Acad Sci USA 2003; 100: 11565-11570.
7. Huseby ES, White J, Crawford F, Vass T, Becker D, Pinilla C et al. How the T cell repertoire becomes peptide and MHC specific. Cell 2005; 122: 247-260.
8. Felix NJ, Donermeyer DL, Horvath S, Walters JJ, Gross ML, Suri A et al. Alloreactive T cells respond specifically to multiple distinct peptide-MHC complexes. Nat Immunol 2007; 8: 388-397.
9. Guimezanes A, Barrett-Wilt GA, Gulden-Thompson P, Shabano-witz J, Engelhard VH, Hunt DF et al. Identification of endogenous peptides recognized by in vivo or in vitro generated alloreactive cytotoxic T lymphocytes: distinct characteristics correlated with CD8 dependence. Eur J Immunol 2001; 31: 421-432.
10. Mazza C, Auphan-Anezin N, Gregoire C, Guimezanes A, Kellenberger C, Roussel A et al. How much can a T-cell antigen receptor adapt to structurally distinct antigenic peptides? EMBO J 2007; 26: 1972-1983.
11. Stanislawski T, Voss RH, Lotz C, Sadovnikova E, Willemsen RA, Kuball J et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol 2001; 2: 962-970.
12. Dutoit V, Guillaume P, Romero P, Cerottini JC, Valmori D. Functional analysis of HLA-A*0201/Melan-A peptide multimer+ CD8+ T cells isolated from an HLA-A*0201- donor: exploring tumor antigen allorestricted recognition. Cancer Immun 2002; 2: 7.
13. Amrolia PJ, Reid SD, Gao L, Schultheis B, Dotti G, Brenner MK et al. Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101: 1007-1014.
14. Pittet MJ, Gati A, Le Gal FA, Bioley G, Guillaume P, de Smedt M et al. Ex vivo characterization of allo-MHC-restricted T cells specific for a single MHC-peptide complex. J Immunol 2006; 176: 2330-2336.
15. Udaka K, Tsomides TJ, Eisen HN. A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell 1992; 69: 989-998.
16. Tallquist MD, Yun TJ, Pease LR. A single T cell receptor recognizes structurally distinct MHC/peptide complexes with high specificity. J Exp Med 1996; 184: 1017-1026.
17. Schuster IG, Busch DH, Eppinger E, Kremmer E, Milosevic S, Hennard C et al. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. Blood 2007; 110: 2931-2939.
18. Toebes M, Coccoris M, Bins A, Rodenko B, Gomez R, Nieuwkoop NJ et al. Design and use of conditional MHC class I ligands. Nat Med 2006; 12: 246-251.
19. Stronen E, Abrahamsen IW, Gaudernack G, Wälchli S, Munthe E, Buus S et al. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumor cells. Scand J Immunol 2009; 69: 319-328.
20. Rosenberg WM, Moss PA, Bell JI. Variation in human T cell receptor V beta and J beta repertoire: analysis using anchor polymerase chain reaction. Eur J Immunol 1992; 22: 541-549.
21. Bae J, Martinson JA, Klingemann HG. Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies. Clin Cancer Res 2005; 11: 1629-1638.
22. Liu J, Roederer M. Differential susceptibility of leukocyte subsets to cytotoxic T cell killing: implications for HIV immunopathogenesis. Cytometry A 2007; 71: 94-104.
23. Turner SJ, Doherty PC, McCluskey J, Rossjohn J. Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006; 6: 883-894.
24. Gavin MA, Bevan MJ. Increased peptide promiscuity provides a rationale for the lack of N regions in the neonatal T cell repertoire. Immunity 1995; 3: 793-800.
25. Savage P, Gao L, Vento K, Cowburn P, Man S, Steven N et al. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen. Blood 2004; 103: 4613-4615.
26. Whitelegg AM, Oosten LE, Jordan S, Kester M, van Halteren AG, Madrigal JA et al. Investigation of peptide involvement in T cell allorecognition using recombinant HLA class I multimers. J Immunol 2005; 175: 1706-1714.
27. Freeman JD, Warren RL, Webb JR, Nelson BH, Holt RA. Profiling the T-cell receptor beta-chain repertoire by massively parallel sequencing. Genome Res 2009; 19: 1817-1824.
28. Derre L, Bruyninx M, Baumgaertner P, Ferber M, Schmid D, Leimgruber A et al. Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues. Proc Natl Acad Sci USA 2008; 105: 15010-15015.
29. Felix NJ, Allen PM. Specificity of T-cell alloreactivity. Nat Rev Immunol 2007; 7: 942-953.
30. Wucherpfennig KW, Allen PM, Celada F, Cohen IR, De Boer R, Garcia KC et al. Polyspecificity of T cell and B cell receptor recognition. Semin Immunol 2007; 19: 216-224.
31. Wucherpfennig KW. T cell receptor crossreactivity as a general property of T cell recognition. Mol Immunol 2004; 40: 1009-1017.
32. Wilson DB, Wilson DH, Schroder K, Pinilla C, Blondelle S, Houghten RA et al. Specificity and degeneracy of T cells. Mol Immunol 2004; 40: 1047-1055.
33. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007; 21: 12-17.
34. De Bueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E. Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T lymphocyte-defined non-MHC antigens. J Immunol 1992; 149: 1788-1794.
35. Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110: 1123-1131.
36. Solal-Celigny P. Safety of rituximab maintenance therapy in follicular lymphomas. Leuk Res 2006; 30 (Suppl 1): S16-S21.
37. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-519.
38. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006; 314: 126-129.
39. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270.
40. Heemskerk MH, Griffioen M, Falkenburg JH. T-cell receptor gene transfer for treatment of leukemia. Cytotherapy 2008; 10: 108-115.
41. Bonavida B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 2007; 26: 3629-3636.
42. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. J Clin Oncol 2003; 21: 1466-1471.
43. Kater AP, van Oers MH, Kipps TJ. Cellular immune therapy for chronic lymphocytic leukemia. Blood 2007; 110: 2811-2818.